Anemia Control in Kidney Transplant Recipients Using Once-Monthly Continuous Erythropoietin Receptor Activator: A Prospective, Observational Study
Table 1
Patient demographics and baseline characteristics at study entry (safety population, ).
Recipient age (years)
51.1 (14.1)
Male recipient, (%)
137 (49.1)
Recipient body mass index (kg/m2)
24.8 (4.2)
Cause of end-stage renal diseasea, (%)
Glomerulonephritis
92 (33.0)
Polycystic kidney
26 (9.3)
Chronic pyelonephritis
25 (9.0)
Hypertensive nephrosclerosis
19 (6.8)
Diabetic nephropathy
15 (5.4)
Other
96 (34.4)
Unknown
18 (6.5)
Donor age (years)
49.3 (14.4)
Living donor, (%)
54 (19.4)
Time since kidney transplantation (years)
7.2 (6.1)
Hb (g/dL)
11.2 (1.2) g/dL
Iron supplementation, (%)b
Any
74 (26.5)
Intravenous iron
23 (8.2)
Oral iron
56 (20.1)
Unspecified
2 (0.7)
Concomitant medication, (%)
Mycophenolic acid
24 (8.6)c
Calcineurin inhibitor
22 (7.9)c
mTOR inhibitor
18 (6.5)c
Angiotensin-converting enzyme inhibitor
107 (38.4)
Angiotensin-II receptor antagonist
95 (34.1)
eGFR (MDRD) at study entry, mL/min/1.73 m2
Mean (SD)
35.3 (16.6)
Median (interquartile range)
33.5 (24.0–44.0)
Serum ferritin, ng/mL
Mean (SD)
198 (523)
Median (interquartile range)
72 (26–179)
Transferrin saturation, %
Mean (SD)
28.3 (11.2)
Median (interquartile range)
28 (20–35)
CRP, mg/L
Mean (SD)
8.4 (21.0)
Median (interquartile range)
3.0 (1.2–6.4)
Previous ESA therapy, (%)
None
55 (19.7)
Darbepoetin alfa
98 (35.1)
C.E.R.A.
45 (16.1)
Epoetin beta
61 (21.9)
Epoetin delta
13 (4.7)
Epoetin alfa
7 (2.5)
Duration of previous ESA therapy, months
Darbepoetin alfa
20.2 (22.3)
C.E.R.A.
3.7 (3.9)
Epoetin beta
19.6 (18.3)
Epoetin delta
16.5 (18.7)
Epoetin alfa
12.8 (9.4)
More than one cause could be listed per patient. bMore than one type could be listed per patient. cData on immunosuppressive therapy were provided in only 43 patients. Continuous variables are shown as mean (SD) unless otherwise stated. C.E.R.A.: continuous erythropoietin receptor activator; CRP: C-reactive protein; eGFR: estimated GFR; ESA: erythropoiesis stimulating agent; MDRD: Modification of Diet in Renal Disease; SD: standard deviation.
